SARS-CoV-2 vaccines are well tolerated in patients with mastocytosis

[1]  Miguel Park,et al.  Utility and futility of skin testing to address concerns surrounding messenger RNA coronavirus disease 2019 vaccine reactions , 2021, Annals of Allergy, Asthma & Immunology.

[2]  A. Peters,et al.  COVID-19 vaccine-related presumed allergic reactions and second dose administration by using a two-step graded protocol. , 2021, Allergy and asthma proceedings.

[3]  E. Walsh,et al.  Graded Administration of Second Dose of Moderna and Pfizer-BioNTech COVID-19 mRNA Vaccines in Patients With Hypersensitivity to First Dose , 2021, Open forum infectious diseases.

[4]  J. Bernstein,et al.  The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach , 2021, The Journal of Allergy and Clinical Immunology: In Practice.

[5]  Paige G. Wickner,et al.  First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing , 2021, The Journal of Allergy and Clinical Immunology: In Practice.

[6]  C. Akin,et al.  Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome , 2021, The Journal of Allergy and Clinical Immunology. in Practice.

[7]  A. Ramsey,et al.  Administration of a Second Dose of the Moderna COVID-19 Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case Reports , 2021, Annals of Internal Medicine.

[8]  M. Triggiani,et al.  COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM) , 2021, The Journal of Allergy and Clinical Immunology: In Practice.

[9]  M. Castells,et al.  mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis , 2021, Journal of Allergy and Clinical Immunology.

[10]  Paige G. Wickner,et al.  mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach , 2020, The Journal of Allergy and Clinical Immunology: In Practice.

[11]  M. Triggiani,et al.  Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions , 2020, Journal of Allergy and Clinical Immunology.

[12]  S. Spector,et al.  Adverse reactions to vaccines practice parameter 2012 update. , 2012, The Journal of allergy and clinical immunology.

[13]  J. Ring,et al.  Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients , 2008, Allergy.